ACTU: actuatetherapeutics.com Price/Earnings to Growth Multiple

Symbol and logo of brand Actuate Therapeutics Inc (ACTU)

The PEG ratio trend reflects market expectations, where the 0.00 mark indicates the valuation level relative to growth rates. However, Actuate Therapeutics, Inc. (ACTU) faces high costs for final trials and a dependence on external funding. A positive reputation within the scientific community and partnerships with global cancer research institutes establish the foundation for the future success of Actuate Therapeutics, Inc.

Price/Earnings to Growth Ratio: Actuate Therapeutics Inc. (ACTU) for 08/14/2024 - 11/15/2026

Analytical breakdowns for actuatetherapeutics.com (ACTU)

General company analysis:ACTU (Actuate Therapeutics, Inc.)
Mass-produced product of Actuate Therapeutics, Inc.

Actuate Therapeutics, Inc. (ACTU) maintains a narrow specialization in a single GSK-3beta inhibitor, creating a high dependency of the asset's value on clinical trial results. By analyzing the PEG ratio, an investor compares the current earnings multiple with business expansion rates, which helps identify an undervalued asset when the ratio is below one; however, the binary risks inherent in biotech necessitate caution when constructing a long-term portfolio.

Who Actuate Therapeutics, Inc. competes with

Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple HALO (halozyme.com)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen (URGN) - Price/Earnings to Growth Ratio|Bicara Bio - Growth-Adjusted Payback Ratio|PSNL (Personalis Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca, Inc. ERAS|PEG Multiple DCTH|YMAB - Price to Earnings Adjusted for Growth Rate|Aura Biosciences Inc - Price/Earnings to Growth Multiple|PEG Multiple Candel Therapeutics CADL|accuray.com - PEG Multiple|SLS: Price/Earnings to Growth Ratio|CTOR: PEG Multiple|TuHURA (HURA) - PEG Multiple|TARA (Protara Therapeutics Inc) - PEG Multiple|FATE: Growth-Adjusted Payback Ratio|PEG Multiple WHWK|TCRX (TScan) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Champions Oncology, Inc. CSBR|XBIT - Price/Earnings to Growth Multiple|CEL-SCI - PEG Multiple|OSTX - PEG Multiple|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|ARTV - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ANL|Price/Earnings to Growth Ratio VERU|PEG Multiple TPST|XLO: Market Cap to Earnings and Growth Ratio|PEG Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Price to Earnings Adjusted for Growth Rate|Kairos Pharma Ltd - PEG Multiple|Market Cap to Earnings and Growth Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Price/Earnings to Growth Ratio|CRIS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple APLM|Tharimmune (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc.)|Genprex - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|PPBT: PEG Multiple|Growth-Adjusted P/E Ratio AONC|BGNE (BeiGene Ltd) - PEG Multiple|CKPT (Checkpoint Therapeutics, Inc) - Company Value to Earnings Growth Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple iCAD Corp ICAD|Price/Earnings to Growth Ratio ikenaoncology.com IKNA|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple